



Supplementary Figure 2. Kaplan-Meier curves for progression-free survival (PFS) (A and B) and overall survival (OS) (C and D) according to early PET response assessed with SULpeak and TLG. (A): SULpeak assessment; median PFS of patients classified with progression 2.5 months (95% confidence interval (CI): 0.7-4.4) and non-progression 2.7 months (95% CI: 2.5-3.0); B: TLG assessment; median PFS of patients classified with progression 2.4 months (95% CI: 1.6-3.3) and non-progression 2.7 months (95% CI: 2.5-2.9); C: SULpeak assessment; median OS of patients classified with progression 2.3 months (95% CI: 1.5-3.1) and non-progression 8.0 months (95% CI: 5.1-11.0); D: TLG assessment; median OS of patients classified with progression 3.2 months (95% CI: 0.0-8.5) and non-progression 8.3 months (95% CI: 4.8-11.9). Differences between groups were calculated using the log-rank test.